PuraPharm Corporation Limited (HKG:1498)

Market Cap	176.57M -8.8%
Revenue (ttm)	346.76M -17.3%
Net Income	-38.56M
EPS	-0.10
Shares Out	535.05M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,500
Average Volume	291,888
Open	0.3350
Previous Close	0.3350
Day's Range	0.3250 - 0.3350
52-Week Range	0.3250 - 0.6500
Beta	0.09
RSI	39.92
Earnings Date	Mar 30, 2026

About PuraPharm Corporation

PuraPharm Corporation Limited, an investment holding company, engages in research, development, production, and sale of concentrated Chinese medicine granule (CCMG) and Chinese healthcare products in Hong Kong, Mainland China, and internationally. It operates through five segments: China CCMG, Hong Kong CCMG, Chinese Healthcare Products, Clinics, and Plantation. The company offers over the counter health products under the PuraGold, Oncozac, Haveron, and Immuzac brand names. It also provides Chinese medicine clinic management system for general...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 469
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1498

Financial Performance

In 2024, PuraPharm Corporation's revenue was 382.09 million, a decrease of -6.09% compared to the previous year's 406.86 million. Losses were -35.44 million, -66.59% less than in 2023.